POSTPONED:

event_image

Event Details

Date:
Sunday, January 1, 1111
6:00 PM - 7:30 PM 
Location:
PwC
300 Madison Avenue
New York, NY
Event type
Lecture / Panel  

Event Description

***Please note that Dr. Robin Robinson lecture “Looming Biothreats, Emerging Infectious Diseases and Medical Countermeasures” has been postponed due to an unforseen meeting in Washington, DC.***

 

Please join the Foreign Policy Association for a talk with Dr. Robin Robinson, Director of the Biomedical Advanced Research and Development Authority and Deputy Assistant Secretary for Preparedness & Response at the U.S. Department of Health and Human Services. 

Mobilizing new assets and infrastructure for development and manufacturing of biothreat MCMs has enabled more rapid and stronger responses to recent emerging outbreaks including H7N9 outbreaks in China last year and the current Ebola epidemic in Africa this year. Dr. Robinson will discuss these new assets and infrastructure and what stronger responses mean for the general American public. 

Dr. Robinson will be speaking as part of the Dame Jillian Sackler Distinguished Lecture Series on Global Health Issues.

Event Speakers

    • Dr. Robin Robinson - Guest of Honor
      Director of the Biomedical Advanced Research and Development Authority and Deputy Assistant Secretary for Preparedness & Response, U.S. Department of Health and Human Services

      Dr. Robin Robinson was appointed in April 2008 as the first director of the newly, created federal agency, Biomedical Advanced Research and Development Authority (BARDA), and Deputy Assistant Secretary in the Office of the Assistant Secretary for Preparedness and Response within HHS by the Pandemic and All-Hazards Preparedness Act of 2006.  BARDA develops and provides medical countermeasures to man-made and natural threats including chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. BARDA meets this mission by supporting product innovation, advanced development, acquisition and stockpiling, and building manufacturing infrastructure. Dr. Robinson led the nation’s effort to develop and manufacture the largest amount of vaccine in U.S. history in response to the 2009 H1N1 pandemic.

       
      Dr. Robinson was recruited by HHS from the vaccine industry in May 2004 to establish a Manhattan-like program with scientific and technical experts to implement the strategic plans and policies for medical countermeasures outlined in the National Strategy for Pandemic Influenza (Nov. 2005). These tactical measures included development, acquisition and establishment of national medical countermeasure stockpiles, and expansion of domestic manufacturing surge capacities for influenza vaccines, antiviral drugs, rapid diagnostics, and non-pharmaceutical countermeasures including respiratory devices. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense’s Clay Dalrymple Award in 2008 and a finalist for the Service to America Medal in 2009.
       
      Dr. Robinson also serves on World Health Organization (WHO) international expert teams on pandemic influenza vaccines. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.

    • Dr. Robin Robinson